Baxter's Orphan Drug Candidate Hits Key Phase 3 Endpoint
Baxter's Orphan Drug Candidate Hits Key Phase 3 Endpoint
(Source: Baxter) Baxter International Inc. announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the …
Read more on Drug Discovery & Development
Drug days behind him, former Oatkan Knight gets another shot at life and football
That meant pain medication. It meant time away from the field, from his teammates, from everything that had kept him anchored. It's a familiar story in sports — injury, pain medication, followed by a need to self-medicate with whatever street drugs …
Read more on The Batavian
More Drug Treatment News 2010 Information…